PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$5.39
+2.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | 1.7M |
| Gross Profit | — | — | — | — | (1.7M) |
| Operating Expenses | |||||
| R&D Expense | 23.4M | 23.8M | 22.8M | 16.1M | 28.0M |
| SG&A Expense | 8.2M | 9.2M | 5.2M | 6.7M | 10.9M |
| General & Admin Expense | 6.4M | 7.2M | 4.3M | 5.5M | 8.0M |
| Selling & Marketing Expense | 1.9M | 2.0M | 945.0K | 1.2M | 2.9M |
| Other Expenses | (32.8M) | — | — | — | (1.7M) |
| Total Operating Expenses | (1.2M) | 33.0M | 28.0M | 22.9M | 37.2M |
| Cost and Expenses | (1.2M) | 33.0M | 28.0M | 22.9M | 38.9M |
| Operating Income (EBIT) | 1.2M | (33.0M) | (28.0M) | (22.9M) | (38.9M) |
| Non-Operating | |||||
| Interest Income | 64.0K | — | 442.0K | 548.0K | 267.0K |
| Interest Expense | 24.0K | 685.0K | 1.5M | 1.7M | 1.3M |
| Net Interest Income | 40.0K | (685.0K) | (1.1M) | (1.2M) | (1.1M) |
| Other Non-Op Income/Expense | (32.7M) | (1.2M) | (951.0K) | (929.0K) | (540.0K) |
| Non-Operating Income (excl Interest) | 32.7M | 512.0K | (574.0K) | (782.0K) | (799.0K) |
| EBT (Pre-Tax Income) | (31.6M) | (34.2M) | (29.0M) | (23.8M) | (39.4M) |
| Income Tax Expense | (53.0K) | 5.0K | 42.0K | 69.0K | 129.0K |
| Bottom Line | |||||
| Net Income | (31.5M) | (34.2M) | (29.0M) | (23.9M) | (39.5M) |
| Earnings from Cont. Ops | (31.5M) | (34.2M) | (29.0M) | (23.9M) | (39.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.5M) | (34.2M) | (29.0M) | (23.9M) | (39.6M) |
| Per Share | |||||
| Basic EPS | ($1.48) | ($2.09) | ($4.91) | ($16.99) | ($61.20) |
| Diluted EPS | ($1.48) | ($2.09) | ($4.91) | ($16.99) | ($61.20) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 22.6M | 16.3M | 5.9M | 1.4M | 1.3M |
| Diluted Shares Outstanding | 22.6M | 16.4M | 5.9M | 1.4M | 1.3M |
| Profitability Metrics | |||||
| EBITDA | (30.8M) | (31.9M) | (25.8M) | (20.3M) | (36.4M) |
| D&A | 770.0K | 1.6M | 1.6M | 1.8M | 1.7M |
| EBIT | (31.5M) | (33.5M) | (27.5M) | (22.1M) | (38.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026